Pancreatic cancer: Long overdue for a new treatment approach

Despite advances in treatments for other cancers, mortality rates in pancreatic cancer have remained unchanged for more than 30 years. For all stages combined, 5-year relative survival is just 7%.1

Indoximod is making strides in metastatic pancreatic cancer research2

NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.3,4

Learn more about the indoximod study in metastatic pancreatic cancer



1. American Cancer Society. Cancer facts and figures 2015. Accessed October 3, 2015. 2. National Institutes of Health. Study of IDO inhibitor in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Accessed October 4, 2015. 3. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 4. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.